References
- Laragh JH. Historical perspective on renin system blockade in the treatment of hypertension. Am J Hyper-tens 1992; 5: 2078–8
- Smith RD., Chiu AT, Wong PC, Herblin WF. Timmermans PBMWM. Pharmacology of nonpeptide angiotensin II receptor antagonists. Annu Rev Pharmacol Toxicol 1992; 32: 135–65
- Weber MA. Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report. Am J Hypertens 1992; 5: 247S–51
- Tsunoda K, Abe K, Hagino T, Misawa S, Imai Y, Yoshinaga K. Hypotensive effect of losartan a nonpeptide angiotensin II receptor in essential Hypertension. Am J Hypertens 1993; 6: 28–32
- Wong PC, Price WA, Jr., Chiu AT, Duncia JV, Carini DJ, Wexler RR. Nonpeptide angiotensin II receptor antagonists XI. Pharmacology of Exp. 3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 255: 211–17
- Timmemans PBMWM, Wong PC, Chiu AT, Herblin WF. Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol Sci 1991; 12: 55–62
- Burnier M, Centeno G, Grouzmann E, Walker P, Waeber B, Brunner HR. In vitro effects of DuP 753, a nonpeptide angiotensin II. on human platelets and rat vascular smooth muscle cells. Am J Hypertens 1991; 4: 438–43
- Ménard J. Critical assessment of combination therapy development. Blood Pressure 1993; 2: 5–9, (Suppl l)
- Cappuccio FP, MncGregor GA. Combination therapy in hypertension. Hypertension, pathophysiology and management, JH Laragh, BM Brenner. Raven Press, New York 1995; 83, 2969
- Sassano P, Chatellier G, Billaud E, Corvol P, Menard J. Comparison of increase in the enalapril dose and addition of hydrochlorothiazide as second-step treatment of hypertensive patients not controlled on enalapril alone. J Cardiovasc Pharmacol 1989; 13: 314–9
- Vidt DG for The Multiclinic Study Group. A controlled multiclinic study to compare the antihypertensive effects of MK-421, hydrochlorothiazide, and MK-421 combined with hydrochlorothiazide in patients with mild to moderate hypertension. J Hypertens 1984; 2: 81–8, (Suppl 2)
- Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin I1 receptor antagonist in healthy subjects. Eur J Clin Pharmacol 1992; 42: 3335
- Dahlöf B, Hansson L, Acosta JH, Bolzano K, Fairhurst G, Ferreira C. Controlled trial of enalapril and hydrochlorothiazide in 200 hypertensive patients. Am J Hypertens 1988; 1: 38–41
- Andrèn L, Weiner L, Svensson A, Hansson L. Enalapril with either a “very low” or “low” dose of hydrochlorothiazide is equally effective in essential hypertension: a double-blind trial in 100 hypertensive patients. J Hypertens 1983; 1: 384–6, (Suppl 2)